Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
Ticker
$AMLX
Sector
Primary listing
Employees
136
Headquarters
Website
AMLX Metrics
BasicAdvanced
$1.5B
-
-$1.53
-0.30
-
Price and volume
Market cap
$1.5B
Beta
-0.3
52-week high
$17.49
52-week low
$3.11
Average daily volume
971K
Financial strength
Current ratio
14.266
Quick ratio
13.98
Long term debt to equity
1.539
Total debt to equity
1.951
Profitability
EBITDA (TTM)
-152.766
Effective tax rate (TTM)
-0.03%
Management effectiveness
Return on assets (TTM)
-36.41%
Return on equity (TTM)
-61.59%
Valuation
Price to book
5.04
Price to tangible book (TTM)
5.04
Price to free cash flow (TTM)
-10.714
Free cash flow yield (TTM)
-9.33%
Free cash flow per share (TTM)
-1.306
Growth
Earnings per share change (TTM)
-65.44%
3-year earnings per share growth (CAGR)
-23.29%
AMLX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $1.5B as of March 17, 2026.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of March 17, 2026.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.3. This means that it has an inverse relation to market volatility.